PUBLIC COMPANY
save$RLMDRELMADA THERAPEUTICS, INC.
$RLMD4.8000+1.05%Coral Gables, FL, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
- phase3A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
- phase3A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
- phase2Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC
- phase3Safety of REL-1017 for Major Depressive Disorder
- phase3A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
- —Individual Patient Esmethadone (REL-1017) Expanded Access Program
- phase3A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that